Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director | February 27, 2026 | March 02, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director · President and CEO | August 24, 2026 | August 24, 2026 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | September 14, 2026 | September 17, 2026 |
| Zosano Pharma CorpZSAN · Entity 12518 | Director | January 02, 2019 | July 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atrium Therapeutics, Inc.
Report date February 27, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2036-02-27 | Direct | 20,000 |
Reported balance
After 2026-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 20,000 · Balance 20,000 F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Kura Oncology, Inc.
Report date August 24, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby One Fish Two Fish Revocable Trust | 479,194 |
Reported balance
After 2026-08-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-24 · Purchase · Acquired 100,000 · Balance 479,194 F1: This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Indirectby Lorax Charitable Remainder Unitrust | 300,000 |
Reported balance
Holding disclosure · report date 2026-08-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,000 |
| Common StockSEC Table I · non-derivative | Direct | 435,456 |
Reported balance
Holding disclosure · report date 2026-08-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 435,456 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
PUMA BIOTECHNOLOGY, INC.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,750 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Sale · Disposed 5,000 · Balance 54,750 F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026 |
| Common StockSEC Table I · non-derivative | IndirectBy Child #1 | 400 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 400 |
| Common StockSEC Table I · non-derivative | IndirectBy Child #2 | 150 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 150 |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026
Zosano Pharma Corp
Report date January 02, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2029-01-02 | Direct | 1,500 |
Reported balance
After 2019-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 1,500 · Balance 1,500 F1: The shares underlying the option shall vest on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest on the first anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 65,091 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 13,711 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 01:13 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 5,000 | $9.10 | $45,500.00 |
DisclosureSEC source: 0001437749-26-030597 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,750 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026 Read SEC document |
| August 24, 2026 Filed Aug 24, 2026 21:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 100,000 | $12.39 | $1,239,000.00 |
DisclosureSEC source: 0001193125-26-363812 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 479,194 F1 · price: This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 20:45 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 100,000 | $11.12 | $1,112,000.00 |
DisclosureSEC source: 0001193125-26-354201 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · by One Fish Two Fish Revocable Trust Disclosed balance after: 379,194 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.87 to $11.31. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 00:16 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 10,800 | $7.20 | $77,748.12 |
DisclosureSEC source: 0001437749-26-020709 · rdgdoc.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,750 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 00:16 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020709 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,550 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 13:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,103 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001193125-26-122938 · ownership.xml · derivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,103 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents stock options exercised. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 13:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,103 | $6.15 | $37,533.45 |
DisclosureSEC source: 0001193125-26-122938 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 435,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents stock options exercised. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:15 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | Not disclosed Strike: $26.09 | Not disclosed |
DisclosureSEC source: 0001193125-26-082251 · ownership.xml · derivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-15 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:15 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,489 | Not disclosed Strike: $39.96 | Not disclosed |
DisclosureSEC source: 0001193125-26-082251 · ownership.xml · derivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,489 shares Expires 2034-06-12 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:15 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,034 | Not disclosed Strike: $33.62 | Not disclosed |
DisclosureSEC source: 0001193125-26-082251 · ownership.xml · derivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,034 shares Expires 2035-06-09 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:15 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 13,711 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082251 · ownership.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| February 27, 2026 Filed Feb 27, 2026 20:15 UTC | Avidity Biosciences, Inc. RNAM · Entity 11854 | Disposition to issuerCommon Stock | 65,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-082251 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 23:00 UTC | Atrium Therapeutics, Inc. RNA · Entity 6185 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001193125-26-085920 · ownership.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-02-27 F1 · derivative.exercise_date: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:31 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 1,120,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004580 · ownership.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,120,000 Underlying: Common Stock · 1,120,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| November 13, 2025 Filed Nov 15, 2025 01:00 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 182,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-283565 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,353 F1 · kind: Represents 1/3rd of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| September 29, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 36,615 | $8.94 | $327,418.65 |
DisclosureSEC source: 0001193125-25-223663 · ownership.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,853 F1 · kind: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on September 27, 2025, resulting in the vesting of 1/6th of the underlying shares. Read SEC document |
| September 27, 2025 Filed Sep 29, 2025 23:30 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 182,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-223663 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,468 Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:28 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 50,000 | $8.20 | $410,145.00 |
DisclosureSEC source: 0001415889-25-023974 · form4-09092025_080937.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,968 F1 · price: This transaction was executed in multiple trades at prices ranging from $8.135 to $8.24. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakesto provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 21:53 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001599901-25-000177 · wk-form4_1757454797.xml · derivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,500 shares Expires 2033-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable as of the date hereof. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 21:53 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 15,000 | $50.00 | $750,000.00 |
DisclosureSEC source: 0001599901-25-000177 · wk-form4_1757454797.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,425 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 21:53 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 14,500 | $50.00 | $725,000.00 |
DisclosureSEC source: 0001599901-25-000177 · wk-form4_1757454797.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,425 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 21:53 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 14,500 | $12.48 | $180,960.00 |
DisclosureSEC source: 0001599901-25-000177 · wk-form4_1757454797.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 13,494 | $6.64 | $89,623.10 |
DisclosureSEC source: 0000950170-25-108844 · ownership.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,968 F3 · price: This transaction was executed in multiple trades at prices ranging from $6.485 to $6.735. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | PurchaseCommon Stock | 36,506 | $5.85 | $213,578.35 |
DisclosureSEC source: 0000950170-25-108844 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,474 F1 · price: This transaction was executed in multiple trades at prices ranging from $5.56 to $5.995. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 409 shares acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · derivative · entry 13 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 7,500 shares Expires 2033-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. F2 · derivative.exercise_date: All shares of common stock subject to this option were fully vested and exercisable as of the date of execution of this option by Reporting Person. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · derivative · entry 12 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. F2 · derivative.exercise_date: All shares of common stock subject to this option were fully vested and exercisable as of the date of execution of this option by Reporting Person. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 17,777 | $45.00 | $799,965.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 8 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By irrevocable trust 4 Disclosed balance after: 17,776 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 17,777 | $45.00 | $799,965.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 7 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By irrevocable trust 3 Disclosed balance after: 17,776 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 15,000 | $45.00 | $675,000.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By irrevocable trust 2 Disclosed balance after: 285,000 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 15,000 | $45.00 | $675,000.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By irrevocable trust 1 Disclosed balance after: 285,000 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 7,500 | $45.00 | $337,500.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,425 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 7,500 | $12.48 | $93,600.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 22,000 | $45.00 | $990,000.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,425 F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 21:42 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 22,000 | $12.03 | $264,660.00 |
DisclosureSEC source: 0001599901-25-000154 · wk-form4_1754689360.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on December 4, 2024. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 23:55 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 10,800 | $3.40 | $36,720.00 |
DisclosureSEC source: 0001437749-25-020721 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,550 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 03/12/2025 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.34 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 14, 2025 00:11 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020358 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,350 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 10,034 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0001599901-25-000119 · wk-form4_1749767160.xml · derivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,034 Underlying: Common Stock · 10,034 shares Expires 2035-06-09 F2 · derivative.exercise_date: This option shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 22:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 6,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-25-000119 · wk-form4_1749767160.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,425 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full on the first to occur of June 10, 2026 or the Issuer's 2026 annual meeting of stockholders, in each case subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 625,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0000950170-25-002046 · ownership.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 01:27 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-021024 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,350 F1 · price: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 22:52 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 13,489 | $0.00 Strike: $39.96 | $0.00 |
DisclosureSEC source: 0001599901-24-000087 · wk-form4_1718405536.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,489 Underlying: Common Stock · 13,489 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 23:27 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,000 | $3.33 | $89,901.90 |
DisclosureSEC source: 0001437749-24-020574 · rdgdoc.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-15-2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.2801 to $3.5801, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 22:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 84,107 | $20.23 | $1,701,484.61 |
DisclosureSEC source: 0000950170-24-008020 · ownership.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2022. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 22:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 84,107 | $6.15 | $517,258.05 |
DisclosureSEC source: 0000950170-24-008020 · ownership.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2022. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 22:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,945 | $20.23 | $140,497.35 |
DisclosureSEC source: 0000950170-24-008020 · ownership.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2022. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 22:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,945 | $4.80 | $33,336.00 |
DisclosureSEC source: 0000950170-24-008020 · ownership.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2022. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 560,000 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0000950170-24-001842 · ownership.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 11:50 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | OtherCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-23-000101 · wk-form4_1702554646.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust FBO Children 3 and 4 Disclosed balance after: 300,000 F1 · kind: Represents a transfer for no value from the Reporting Person to a trust established for the benefit of the Reporting Person's family. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 11:50 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | OtherCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-23-000101 · wk-form4_1702554646.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 13,711 F1 · kind: Represents a transfer for no value from the Reporting Person to a trust established for the benefit of the Reporting Person's family. Read SEC document |
| December 12, 2023 Filed Dec 14, 2023 11:50 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | OtherCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001599901-23-000101 · wk-form4_1702554646.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust FBO Children 1 and 2 Disclosed balance after: 300,000 F1 · kind: Represents a transfer for no value from the Reporting Person to a trust established for the benefit of the Reporting Person's family. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.